Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 10;17(7):1601.
doi: 10.3390/s17071601.

Rapid Surface Enhanced Raman Scattering (SERS) Detection of Sibutramine Hydrochloride in Pharmaceutical Capsules with a β-Cyclodextrin- Ag/Polyvivnyl Alcohol Hydrogel Substrate

Affiliations

Rapid Surface Enhanced Raman Scattering (SERS) Detection of Sibutramine Hydrochloride in Pharmaceutical Capsules with a β-Cyclodextrin- Ag/Polyvivnyl Alcohol Hydrogel Substrate

Lei Ouyang et al. Sensors (Basel). .

Abstract

Sibutramine hydrochloride (SH) is a banned weight-loss drug, but its illegal addition to health products is still rampant. This suggests a very urgent need for a fast and precise detection method for SH. Surface Enhanced Raman Scattering (SERS) is a promising candidate for this purpose, but the weak affinity between SH and bare metal limits its direct SERS detection. In the present work, β-cyclodextrin was capped in situ onto the surface of Ag nanoparticles to function as a scaffold to capture SH. The obtained Ag nanoparticles were encapsulated into polyvinyl alcohol (PVA) to fabricate a SERS active hydrogel with excellent reproducibility. A facile SERS strategy based on such substrate was proposed for trace SH quantification with a linear range of 7.0-150.0 µg·mL-1, and a detection limit low to 3.0 µg·mL-1. It was applied to analyze seven types of commercial slimming capsules with satisfactory results, showing good prospect for real applications.

Keywords: Surface Enhanced Raman Scattering; polyvinyl alcohol; sibutramine hydrochloride; β-cyclodextrin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Characterization of the β-CD-Ag/PVA substrate. (a) Photograph of the β-CD-Ag/PVA sol before hydrogel formation; (b) Photograph of the β-CD-Ag/PVA hydrogel; (c,d) SEM images of the β-CD-Ag/PVA hydrogel at different magnification.
Figure 2
Figure 2
(a) Comparison of the SERS performance for SH detection with different substrates; (b) Adsorption kinetics of SH on PVA, Ag/PVA and β-CD-Ag/PVA (298 K).
Figure 3
Figure 3
(a) UV-Vis spectra of Ag NP suspensions prepared with different synthesis pH values ranging from 9.5 to 13.35; (b) SERS spectra of SH on β-CD/Ag NPs synthesized at different pH values; (c) UV-Vis spectra of Ag NPs obtained at different ratio of AgNO3 and β-CD: 0.2:1, 0.5:1, 1:1, 3:1, 6:1, and 12:1; (d) TEM micrograph of β-CD/Ag obtained with AgNO3 and β-CD at a ratio of 1:1 ratio.
Figure 4
Figure 4
SERS intensity change of SH at 1594 cm−1 using β-CD-Ag/PVA with different densities of β-CD-Ag NPs (from 1 to 9 mmol·L−1).
Figure 5
Figure 5
Raman responses of the substrate β-CD-Ag/PVA after being soaked in water at different pH values.
Figure 6
Figure 6
(a) SERS spectra of different concentrations of SH; (b) A correlation between the Raman intensity at 1594 cm−1 and the concentration of SH. The inset in (b) showed the linear range within 7–150 µg·mL−1 between the intensity at 1594 cm−1 and the concentration of SH.
Figure 7
Figure 7
(a) Results of confirming the selectivity for SH detection; (b) SERS intensity (at the 1594 cm−1 peak) of 100 μg mL−1 SH on eight batches of β-CD-Ag/PVA substrates, five spots were randomly chosen for each batch of substrate.

Similar articles

Cited by

References

    1. Radhakrishna T., Narayana C.L., Rao D.S., Vyas K., Reddy G.O. LC method for the determination of assay and purity of sibutramine hydrochloride and its enantiomers by chiral chromatography. J. Pharm. Biomed. Anal. 2000;22:627–639. doi: 10.1016/S0731-7085(99)00303-9. - DOI - PubMed
    1. Park J.-Y., Kim K.-A., Park P.-W., Suh K.-H., Lee G.S. Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: A randomized, open-label, two-period, comparative crossover study. Clin. Ther. 2004;26:2092–2101. doi: 10.1016/j.clinthera.2004.12.012. - DOI - PubMed
    1. Halpern A., Leite C.C., Herszkowicz N., Barbato A., Costa A.P.A. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study. Rev. Hosp. Clin. 2002;57:98–102. doi: 10.1590/S0041-87812002000300003. - DOI - PubMed
    1. Buckett W.R., Thomas P.C., Luscombe G.P. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog. Neuro-Psychopharm. Biol. Psychiatry. 1988;12:575–584. doi: 10.1016/0278-5846(88)90003-6. - DOI - PubMed
    1. Elfhag K., Rössner S., Barkeling B., Rooth P. Sibutramine treatment in obesity: Initial eating behaviour in relation to weight loss results and changes in mood. Pharmacol. Res. 2005;51:159–163. doi: 10.1016/j.phrs.2004.07.005. - DOI - PubMed

LinkOut - more resources